Проблема остеопороза: новыетерапевтические решенияи долговременная клиническаяэффективность

1. Seeman E, Delmas PD. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250–61.
2. Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69 (3): 121–9.
3. Bonnelye E, Chabadel A, Saitel F. Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorbtion in vitro. Bone 2008; 42: 129–38.
4. Barbara A, Delannoy P, Denis BG et al. Normal matrix mineralization induced by strontium ranelate in MC3T3-E, osteogenic cells. Metabolism 2004; 53: 532–7.
5. Canalis E, Hot M, Deloffre P et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18 (6): 517–23.
6. Chattopadhyay N, Quinn SJ, Kifer O et al. The calcium-sensing receptor (CaR) is involved in strontium ranelate– induced osteoblast proliferation. Biochem Pharmacol 2007; 74: 438–47.
7. Baron R, Tsouderos Y. In vitro effects of S12911–2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002; 450: 11–7.
8. Atkins GJ, Welldon KJ, Halbout P, Findlay DM. Strontium ranelate treatment of primary osteoblasts promotes an osteocyte – like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009; 20: 653–64.
9. Arlot ME, Jiang Y, Genant HK et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008; 23 (3): 215–22.
10. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 359: 459–68.
11. Collette J, Reginster JY, Bruyere O et al. Dissociation between bone formation and bone resorption evidence by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Calcif Tissue Int 2007; 80 (Suppl. 1): S120.
12. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816–22.
13. Roux C, Fechtenbaum J, Kolta S et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008; 67: 1736–8.
14. Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral an vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58 (6): 1687–95.
15. Seeman E, Devogelaer JP, Lorence R et al. Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia. J Bone Miner Res 2008; 23 (3): 433–8.
16. Bruyere O, Delferriere D, Roux C et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008; 67 (3): 335–9.
17. Alexandersen P, Karsdal MA, Quist P et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2007; 40 (1): 218–22.